WO2002014358A3 - Novel secreted proteins and their uses - Google Patents

Novel secreted proteins and their uses Download PDF

Info

Publication number
WO2002014358A3
WO2002014358A3 PCT/US2001/021124 US0121124W WO0214358A3 WO 2002014358 A3 WO2002014358 A3 WO 2002014358A3 US 0121124 W US0121124 W US 0121124W WO 0214358 A3 WO0214358 A3 WO 0214358A3
Authority
WO
WIPO (PCT)
Prior art keywords
secreted proteins
novel secreted
useful
nucleic acids
novel
Prior art date
Application number
PCT/US2001/021124
Other languages
French (fr)
Other versions
WO2002014358A2 (en
Inventor
Brian Taylor Edmonds
Radmila Micanovic
Weijia Ou
Eric Wen Su
Sheng-Hung Rainbow Tschang
He Wang
Original Assignee
Lilly Co Eli
Brian Taylor Edmonds
Radmila Micanovic
Weijia Ou
Eric Wen Su
Sheng-Hung Rainbow Tschang
He Wang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli, Brian Taylor Edmonds, Radmila Micanovic, Weijia Ou, Eric Wen Su, Sheng-Hung Rainbow Tschang, He Wang filed Critical Lilly Co Eli
Priority to US10/343,348 priority Critical patent/US20040038242A1/en
Priority to AU2001280471A priority patent/AU2001280471A1/en
Priority to EP01958861A priority patent/EP1309614A2/en
Publication of WO2002014358A2 publication Critical patent/WO2002014358A2/en
Publication of WO2002014358A3 publication Critical patent/WO2002014358A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

The present invention provides nucleic acid sequences encoding novel human proteins. These novel nucleic acids are useful for constructing the claimed DNA vectors and host cells of the invention and for preparing the claimed nucleic acids, recombinant proteins and antibodies that are useful in the claimed methods and medical uses.
PCT/US2001/021124 2000-08-11 2001-07-30 Novel secreted proteins and their uses WO2002014358A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US10/343,348 US20040038242A1 (en) 2001-07-30 2001-07-30 Novel secreted proteins and their uses
AU2001280471A AU2001280471A1 (en) 2000-08-11 2001-07-30 Novel secreted proteins and their uses
EP01958861A EP1309614A2 (en) 2000-08-11 2001-07-30 Novel secreted proteins and their uses

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US22464200P 2000-08-11 2000-08-11
US60/224,642 2000-08-11
US24177900P 2000-10-19 2000-10-19
US60/241,779 2000-10-19

Publications (2)

Publication Number Publication Date
WO2002014358A2 WO2002014358A2 (en) 2002-02-21
WO2002014358A3 true WO2002014358A3 (en) 2003-03-13

Family

ID=26918895

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/021124 WO2002014358A2 (en) 2000-08-11 2001-07-30 Novel secreted proteins and their uses

Country Status (3)

Country Link
EP (1) EP1309614A2 (en)
AU (1) AU2001280471A1 (en)
WO (1) WO2002014358A2 (en)

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8008332B2 (en) 2006-05-31 2011-08-30 Takeda San Diego, Inc. Substituted indazoles as glucokinase activators
US8034822B2 (en) 2006-03-08 2011-10-11 Takeda San Diego, Inc. Glucokinase activators
US8124617B2 (en) 2005-09-01 2012-02-28 Takeda San Diego, Inc. Imidazopyridine compounds
US8163779B2 (en) 2006-12-20 2012-04-24 Takeda San Diego, Inc. Glucokinase activators
US8173645B2 (en) 2007-03-21 2012-05-08 Takeda San Diego, Inc. Glucokinase activators
US8859741B2 (en) 2007-08-23 2014-10-14 Amgen Inc. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
US8883157B1 (en) 2013-12-17 2014-11-11 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US8945560B1 (en) 2014-07-15 2015-02-03 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8986694B1 (en) 2014-07-15 2015-03-24 Kymab Limited Targeting human nav1.7 variants for treatment of pain
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8992927B1 (en) 2014-07-15 2015-03-31 Kymab Limited Targeting human NAV1.7 variants for treatment of pain
US8999341B1 (en) 2014-07-15 2015-04-07 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US9034332B1 (en) 2014-07-15 2015-05-19 Kymab Limited Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
US9062105B1 (en) 2014-07-15 2015-06-23 Kymab Limited Precision Medicine by targeting VEGF-A variants for treatment of retinopathy
US9109034B1 (en) 2014-07-15 2015-08-18 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
US9139648B1 (en) 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
US9150660B1 (en) 2014-07-15 2015-10-06 Kymab Limited Precision Medicine by targeting human NAV1.8 variants for treatment of pain
US9266961B2 (en) 2012-06-15 2016-02-23 Genentech, Inc. Anti-PCSK9 antibodies, formulations, dosing, and methods of use

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030149238A1 (en) * 2000-02-14 2003-08-07 Pankaj Agarwal Novel compounds
US7247717B2 (en) 2000-11-14 2007-07-24 Bristol-Myers Squibb Company Polynucleotide encoding a novel human serpin secreted from lymphoid cells, LSI-01
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
US20100136028A1 (en) 2006-11-07 2010-06-03 Sparrow Carl P Antagonists of pcsk9
WO2008118386A2 (en) 2007-03-27 2008-10-02 Merck & Co., Inc. Method for detecting autoprocessed, secreted pcsk9
AR070316A1 (en) 2008-02-07 2010-03-31 Merck & Co Inc PCSK9 ANTAGONISTS (SUBTILISINE-KEXINA TYPE 9 PROPROTEIN)
AR070315A1 (en) 2008-02-07 2010-03-31 Merck & Co Inc ANTIBODIES 1B20 ANTAGONISTS OF PCSK9
WO2010068526A1 (en) 2008-12-12 2010-06-17 Merck Sharp & Dohme Corp. Pcsk9 immunoassay
CN102596249A (en) 2009-10-30 2012-07-18 默沙东公司 AX1 and AX189 PCSK9 antagonists and variants
CN102639150A (en) 2009-10-30 2012-08-15 默沙东公司 AX213 and AX132 PCSK9 antagonists and variants
SI3342786T1 (en) 2010-01-29 2022-01-31 Chugai Seiyaku Kabushiki Kaisha Anti-dll3 antibody
AR087715A1 (en) 2011-09-16 2014-04-09 Lilly Co Eli ANTI PCSK9 ANTIBODIES AND USES OF THE SAME
CN104520324A (en) 2012-02-24 2015-04-15 施特姆森特Rx股份有限公司 DLL3 modulators and methods of use
TR201908761T4 (en) 2013-02-22 2019-07-22 Abbvie Stemcentrx Llc Antidll3-antibody-pbd conjugates and their uses.
CN105848671B (en) 2013-08-28 2019-12-13 艾伯维施特姆森特克斯有限责任公司 Site-specific antibody conjugation methods and compositions
US9051378B1 (en) 2014-07-15 2015-06-09 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9067998B1 (en) 2014-07-15 2015-06-30 Kymab Limited Targeting PD-1 variants for treatment of cancer
US9045548B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment
EP3107576A4 (en) 2014-02-21 2017-09-06 Abbvie Stemcentrx LLC Anti-dll3 antibodies and drug conjugates for use in melanoma
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
CN110352242A (en) 2016-12-23 2019-10-18 哈佛大学的校长及成员们 The gene editing of PCSK9
US11667713B2 (en) 2017-12-28 2023-06-06 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent
BR112022019498A2 (en) 2020-03-31 2022-11-16 Chugai Pharmaceutical Co Ltd DLL3 TARGETING MULTISPECIFIC ANTIGEN-BINDING MOLECULES AND THEIR USE

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999006443A1 (en) * 1997-07-31 1999-02-11 The Johns Hopkins University School Of Medicine Growth differentiation factor, lefty-2
WO1999009198A1 (en) * 1997-08-21 1999-02-25 Human Genome Sciences, Inc. Human nodal and lefty homologues
WO1999029718A2 (en) * 1997-12-10 1999-06-17 Genetics Institute, Inc. Bone morphogenetic protein (bmp)-17 and bmp-18 and compositions thereof
US5916751A (en) * 1996-08-27 1999-06-29 University Of South Florida Method for the diagnosis of selected adenocarcinomas
WO2000066068A2 (en) * 1999-04-29 2000-11-09 North Shore Long Island Jewish Research Corporation Method for inducing growth and enhancing survival of nervous tissue

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916751A (en) * 1996-08-27 1999-06-29 University Of South Florida Method for the diagnosis of selected adenocarcinomas
WO1999006443A1 (en) * 1997-07-31 1999-02-11 The Johns Hopkins University School Of Medicine Growth differentiation factor, lefty-2
WO1999009198A1 (en) * 1997-08-21 1999-02-25 Human Genome Sciences, Inc. Human nodal and lefty homologues
WO1999029718A2 (en) * 1997-12-10 1999-06-17 Genetics Institute, Inc. Bone morphogenetic protein (bmp)-17 and bmp-18 and compositions thereof
WO2000066068A2 (en) * 1999-04-29 2000-11-09 North Shore Long Island Jewish Research Corporation Method for inducing growth and enhancing survival of nervous tissue

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KOSAKI K ET AL: "Characterization and mutation analysis of human LEFTY A and LEFTY B, homologues of murine genes implicated in left-right axis development.", AMERICAN JOURNAL OF HUMAN GENETICS, vol. 64, no. 3, March 1999 (1999-03-01), pages 712 - 721, XP002210149, ISSN: 0002-9297 *

Cited By (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8124617B2 (en) 2005-09-01 2012-02-28 Takeda San Diego, Inc. Imidazopyridine compounds
US8034822B2 (en) 2006-03-08 2011-10-11 Takeda San Diego, Inc. Glucokinase activators
US8008332B2 (en) 2006-05-31 2011-08-30 Takeda San Diego, Inc. Substituted indazoles as glucokinase activators
US8394843B2 (en) 2006-05-31 2013-03-12 Takeda California, Inc. Substituted isoindoles as glucokinase activators
US8163779B2 (en) 2006-12-20 2012-04-24 Takeda San Diego, Inc. Glucokinase activators
US8173645B2 (en) 2007-03-21 2012-05-08 Takeda San Diego, Inc. Glucokinase activators
US8859741B2 (en) 2007-08-23 2014-10-14 Amgen Inc. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
US8871914B2 (en) 2007-08-23 2014-10-28 Amgen, Inc. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
US8871913B2 (en) 2007-08-23 2014-10-28 Amgen Inc. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
US8883983B2 (en) 2007-08-23 2014-11-11 Amgen Inc. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
US8889834B2 (en) 2007-08-23 2014-11-18 Amgen Inc. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
US9493576B2 (en) 2007-08-23 2016-11-15 Amgen Inc. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
US8981064B2 (en) 2007-08-23 2015-03-17 Amgen Inc. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
US9266961B2 (en) 2012-06-15 2016-02-23 Genentech, Inc. Anti-PCSK9 antibodies, formulations, dosing, and methods of use
US8883157B1 (en) 2013-12-17 2014-11-11 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US9109034B1 (en) 2014-07-15 2015-08-18 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
US8992927B1 (en) 2014-07-15 2015-03-31 Kymab Limited Targeting human NAV1.7 variants for treatment of pain
US8999341B1 (en) 2014-07-15 2015-04-07 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US9023359B1 (en) 2014-07-15 2015-05-05 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9034331B1 (en) 2014-07-15 2015-05-19 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9034332B1 (en) 2014-07-15 2015-05-19 Kymab Limited Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
US9062105B1 (en) 2014-07-15 2015-06-23 Kymab Limited Precision Medicine by targeting VEGF-A variants for treatment of retinopathy
US8986694B1 (en) 2014-07-15 2015-03-24 Kymab Limited Targeting human nav1.7 variants for treatment of pain
US9139648B1 (en) 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
US9150660B1 (en) 2014-07-15 2015-10-06 Kymab Limited Precision Medicine by targeting human NAV1.8 variants for treatment of pain
US9187562B1 (en) 2014-07-15 2015-11-17 Kymab Limited Methods for treating anaemia
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US9303089B2 (en) 2014-07-15 2016-04-05 Kymab Limited Methods of treating anaemia
US9394568B2 (en) 2014-07-15 2016-07-19 Kymab Limited Methods of treating anaemia
US9428578B2 (en) 2014-07-15 2016-08-30 Kymab Limited Methods of treating anaemia
US9439963B2 (en) 2014-07-15 2016-09-13 Kymab Limited Methods of treating anaemia
US8945560B1 (en) 2014-07-15 2015-02-03 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R

Also Published As

Publication number Publication date
EP1309614A2 (en) 2003-05-14
WO2002014358A2 (en) 2002-02-21
AU2001280471A1 (en) 2002-02-25

Similar Documents

Publication Publication Date Title
WO2002014358A3 (en) Novel secreted proteins and their uses
WO2002008277A3 (en) Nucleic acids, vectors, host cells, polypeptides, and uses thereof
WO1999031236A3 (en) EXTENDED cDNAs FOR SECRETED PROTEINS
WO2001000806A3 (en) Dna's encoding proteins with signal peptides
WO2002059315A3 (en) Human nucleic acids and polypeptides and methods of use thereof
WO2001032882A3 (en) Nucleic acids and proteins from group b streptococcus
WO2002032939A3 (en) Secreted proteins and their uses
WO2001087978A3 (en) Human abc transporter and its use
WO2002026801A3 (en) Secreted proteins and their uses
WO2002048361A3 (en) Novel secreted proteins and their uses
WO2002016578A3 (en) Secreted proteins and methods of using same
WO2001092493A3 (en) 21956 and 25856, human aminopeptidases and uses thereof
WO2002090500A3 (en) Novel human proteins, polynucleotides encoding them and methods of using the same
WO2002012475A3 (en) C1q-related factor, homologous polypeptides and therapeutic uses thereof
EP1529843A3 (en) Novel secreted proteins and their uses
WO2003029778A3 (en) Novel secreted proteins and their uses
WO2002074960A3 (en) 38650, 28472, 5495, 65507, 81588 and 14354 methods and compositions of human proteins and uses thereof
WO2004013281A3 (en) Novel proteins and their uses
WO2003083048A3 (en) Novel secreted proteins and their uses
WO2003012121A3 (en) Collagen xxii, a novel human collagen and uses thereof
WO2002048187A3 (en) Secretion signal peptides, their dna sequences, expression vectors for eukaryotic cells that can be produced with the same, and use thereof for biotechnological production of proteins
WO2002046408A3 (en) Human proteins, polynucleotides encoding them and methods of using the same
WO2004044126A3 (en) Novel proteins and their uses
WO2002016579A8 (en) Nucleic acids, vectors, host cells, polypeptides and uses thereof
WO2001075076A3 (en) 33167, a novel human hydrolase and uses therefor

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 10343348

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2001958861

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001958861

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2001958861

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP